Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/hepatitis-c-virus-amino-acid-sequence-diversity-correlates-with-the-VilEJvMY3n
References (47)
-
M. Saraste, G. Semenza (2000)
FEBS LettFEBS Letters, 476
-
P Simmonds, EC Holmes, TA Cha, SW Chan, F McOmish, B Irvine, E Beall, PL Yap, J Kolberg, MS Urdea (1993)
Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS5 regionJ Gen Virol, 74
-
K. Tamura, J. Dudley, M. Nei, Sudhir Kumar (2007)
MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0.Molecular biology and evolution, 24 8
-
N. Cannon, M. Donlin, Xiaofeng Fan, R. Aurora, J. Tavis (2008)
Hepatitis C Virus Diversity and Evolution in the Full Open-Reading Frame during Antiviral TherapyPLoS ONE, 3
-
Y. Jeong, B. Kim (2003)
Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection -
J. Feld, J. Hoofnagle (2005)
Mechanism of action of interferon and ribavirin in treatment of hepatitis CNature, 436
-
P. Simmonds (2004)
Genetic diversity and evolution of hepatitis C virus--15 years on.The Journal of general virology, 85 Pt 11
-
MJ Alter (2007)
Epidemiology of hepatitis C virus infectionWorld J Gastroenterol, 13
-
E. Steinmann, F. Penin, S. Kallis, A. Patel, R. Bartenschlager, T. Pietschmann (2007)
Hepatitis C Virus p7 Protein Is Crucial for Assembly and Release of Infectious VirionsPLoS Pathogens, 3
-
W. Hofmann, S. Zeuzem, C. Sarrazin (2005)
Hepatitis C virus-related resistance mechanisms to interferon α-based antiviral therapyJournal of Clinical Virology, 32
-
María González, Luis Carrasco (2003)
ViroporinsFEBS Letters, 552
-
Yinghong Ma, Manu Anantpadma, J. Timpe, Saravanabalaji Shanmugam, Sher Singh, S. Lemon, M. Yi (2010)
Hepatitis C Virus NS2 Protein Serves as a Scaffold for Virus Assembly by Interacting with both Structural and Nonstructural ProteinsJournal of Virology, 85
-
M. Gale, Eileen Foy (2005)
Evasion of intracellular host defence by hepatitis C virusNature, 436
-
Ester Aparicio, S. Franco, M. Parera, C. Andrés, C. Tural, B. Clotet, M. Martínez (2011)
Complexity and Catalytic Efficiency of Hepatitis C Virus (HCV) NS3 and NS4A Protease Quasispecies Influence Responsiveness to Treatment with Pegylated Interferon plus Ribavirin in HCV/HIV-Coinfected PatientsJournal of Virology, 85
-
Xiaogang Xiang, Jie Lu, Zhi-xia Dong, Hui-juan Zhou, Wanyin Tao, Q. Guo, Xia-qiu Zhou, S. Bao, Q. Xie, Jin Zhong (2011)
Viral sequence evolution in Chinese genotype 1b chronic hepatitis C patients experiencing unsuccessful interferon treatment.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases, 11 2
-
Eileen Foy, Kui Li, R. Sumpter, Y. Loo, C. Johnson, Chunfu Wang, P. Fish, M. Yoneyama, T. Fujita, S. Lemon, M. Gale (2005)
Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling.Proceedings of the National Academy of Sciences of the United States of America, 102 8
-
J. Bukh, Roger Miller, R. Purcell (1995)
Genetic Heterogeneity of Hepatitis C Virus: Quasispecies and GenotypesSeminars in Liver Disease, 15
-
Eileen Foy, Kui Li, Chunfu Wang, R. Sumpter, M. Ikeda, S. Lemon, M. Gale (2003)
Regulation of Interferon Regulatory Factor-3 by the Hepatitis C Virus Serine ProteaseScience, 300
-
M. Donlin, N. Cannon, E. Yao, Jia Li, A. Wahed, Milton Taylor, S. Belle, A. Bisceglie, R. Aurora, J. Tavis (2007)
Pretreatment Sequence Diversity Differences in the Full-Length Hepatitis C Virus Open Reading Frame Correlate with Early Response to TherapyJournal of Virology, 81
-
M. Yi, Yinghong Ma, J. Yates, S. Lemon (2006)
Compensatory Mutations in E1, p7, NS2, and NS3 Enhance Yields of Cell Culture-Infectious Intergenotypic Chimeric Hepatitis C VirusJournal of Virology, 81
-
M. Manns, J. McHutchison, S. Gordon, V. Rustgi, M. Shiffman, R. Reindollar, Z. Goodman, K. Koury, M. Ling, J. Albrecht (2001)
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trialThe Lancet, 358
-
M. Ghany, D. Strader, David Thomas, L. Seeff (2009)
Diagnosis, management, and treatment of hepatitis C: An updateHepatology, 49
-
Christopher Jones, Catherine Murray, Dawnnica Eastman, Jodie Tassello, C. Rice (2007)
Hepatitis C Virus p7 and NS2 Proteins Are Essential for Production of Infectious VirusJournal of Virology, 81
-
B. Robertson, G. Myers, C. Howard, T. Brettin, J. Bukh, B. Gaschen, T. Gojobori, G. Maertens, M. Mizokami, O. Nainan, S. Netesov, K. Nishioka, T. Shin-I, P. Simmonds, D. Smith, L. Stuyver, A. Weiner (1998)
Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardizationArchives of Virology, 143
-
P. Marcellin (1999)
Hepatitis C: the clinical spectrum of the disease.Journal of hepatology, 31 Suppl 1
-
N. Leone, M. Rizzetto (2005)
Natural history of hepatitis C virus infection: from chronic hepatitis to cirrhosis, to hepatocellular carcinoma.Minerva gastroenterologica e dietologica, 51 1
-
W. Hofmann, S. Zeuzem, C. Sarrazin (2005)
Hepatitis C virus-related resistance mechanisms to interferon alpha-based antiviral therapy.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology, 32 2
-
T. Pietschmann, A. Kaul, G. Koutsoudakis, A. Shavinskaya, S. Kallis, E. Steinmann, K. Abid, F. Negro, M. Dreux, F. Cosset, R. Bartenschlager (2006)
Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras.Proceedings of the National Academy of Sciences of the United States of America, 103 19
-
(2011)
Complexity and catalytic efficiency of hepatitis C virus (HCV) NS3 and NS4A protease quasispecies 1120 -
J. Pawlotsky (2004)
Treating hepatitis C in "difficult-to-treat" patients.The New England journal of medicine, 351 5
-
M. Thod (2004)
Global Burden of Disease (GBD) for Hepatitis CThe Journal of Clinical Pharmacology, 44
-
Edinburgh Research Explorer Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region -
Y. Hutin, M. Kitler, G. Dore, G. Armstrong, G. Dusheiko, P. Grob, M. Kew, P. Marcellin, L. Seeff, P. Beutels, Christopher Nelson, C. Stein, P. Zurn, G. Clifford, R. Vranckx, A. Alberti, Z. Hallaj, S. Hadler, D. Lavanchy (2004)
Global Burden of Disease (GBD) for Hepatitis C The Global Burden of Hepatitis C Working Group -
Y. Hutin, M. Kitler, G. Dore, J. Perz, G. Armstrong, G. Dusheiko, H. Ishibashi, P. Grob, M. Kew, P. Marcellin, L. Seeff, P. Beutels, Christopher Nelson, C. Stein, P. Zurn, G. Clifford, R. Vranckx, A. Alberti, Z. Hallaj, S. Hadler, D. Lavanchy (2004)
Global burden of disease (GBD) for hepatitis C -
P. Kaukinen, M. Sillanpää, S. Kotenko, R. Lin, J. Hiscott, K. Melén, I. Julkunen (2006)
Hepatitis C virus NS2 and NS3/4A proteins are potent inhibitors of host cell cytokine/chemokine gene expressionVirology Journal, 3
-
M. Donlin, N. Cannon, R. Aurora, Jia Li, A. Wahed, A. Bisceglie, J. Tavis (2010)
Contribution of Genome-Wide HCV Genetic Differences to Outcome of Interferon-Based Therapy in Caucasian American and African American PatientsPLoS ONE, 5
-
K. Ukai, M. Ishigami, K. Yoshioka, Naoto Kawabe, Y. Katano, Kazuhiko Hayashi, T. Honda, M. Yano, H. Goto (2006)
Mutations in carboxy-terminal part of E2 including PKR/eIF2alpha phosphorylation homology domain and interferon sensitivity determining region of nonstructural 5A of hepatitis C virus 1b: their correlation with response to interferon monotherapy and viral load.World journal of gastroenterology, 12 23
-
P. Simmonds, J. Bukh, C. Combet, G. Deléage, N. Enomoto, S. Feinstone, P. Halfon, G. Inchauspe, Carla Kuiken, G. Maertens, M. Mizokami, D. Murphy, H. Okamoto, J. Pawlotsky, F. Penin, E. Sablon, T. Shin-I, L. Stuyver, H. Thiel, S. Viazov, A. Weiner, A. Widell (2005)
Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypesHepatology, 42
-
Ching-Sheng Hsu, J. Kao (2011)
Boceprevir for chronic HCV genotype 1 infection.The New England journal of medicine, 365 2
-
Zhi Liu, D. Netski, Q. Mao, O. Laeyendecker, J. Ticehurst, Xiao-hong Wang, David Thomas, S. Ray (2004)
Accurate Representation of the Hepatitis C Virus Quasispecies in 5.2-Kilobase AmpliconsJournal of Clinical Microbiology, 42
-
B Robertson, G Myers, C Howard, T Brettin, J Bukh, B Gaschen, T Gojobori, G Maertens, M Mizokami, O Nainan, S Netesov, K Nishioka, IT Shin, P Simmonds, D Smith, L Stuyver, A Weiner (1998)
Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International committee on virus taxonomyArch Virol, 143
-
I. Jacobson, J. McHutchison, G. Dusheiko, A. Bisceglie, K. Reddy, N. Bzowej, P. Marcellin, A. Muir, P. Ferenci, R. Flisiak, J. George, M. Rizzetto, D. Shouval, R. Solá, R. Terg, E. Yoshida, N. Adda, L. Bengtsson, A. Sankoh, Tara Kieffer, S. George, R. Kauffman, S. Zeuzem, V. Phar (2011)
Telaprevir for previously untreated chronic hepatitis C virus infection.The New England journal of medicine, 364 25
-
N. Pavio, M. Lai (2003)
The hepatitis C virus persistence: how to evade the immune system?Journal of Biosciences, 28
-
Ling Lu, T. Nakano, Yun-shao He, Yongshui Fu, C. Hagedorn, B. Robertson (2005)
Hepatitis C virus genotype distribution in China: Predominance of closely related subtype 1b isolates and existence of new genotype 6 variantsJournal of Medical Virology, 75
-
R. Esteban (1993)
Epidemiology of hepatitis C virus infection.Journal of hepatology, 17 Suppl 3
-
Chao Lin, B. Lindenbach, B. Prágai, D. Mccourt, C. Rice (1994)
Processing in the hepatitis C virus E2-NS2 region: identification of p7 and two distinct E2-specific products with different C terminiJournal of Virology, 68
-
J. McHutchison, E. Lawitz, M. Shiffman, A. Muir, G. Galler, J. McCone, L. Nyberg, William Lee, R. Ghalib, E. Schiff, J. Galati, B. Bacon, Mitchell Davis, P. Mukhopadhyay, K. Koury, S. Noviello, L. Pedicone, C. Brass, J. Albrecht, M. Sulkowski (2009)
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.The New England journal of medicine, 361 6
- Publisher
- Springer Journals
- Copyright
- Copyright © 2012 by Springer-Verlag
- Subject
- Biomedicine; Virology; Infectious Diseases; Medical Microbiology
- ISSN
- 0304-8608
- eISSN
- 1432-8798
- DOI
- 10.1007/s00705-012-1283-1
- pmid
- 22426896
- Publisher site
- See Article on Publisher Site
Abstract
Evidence has shown that the p7, NS2 and NS3 genes affect the outcome of pegylated-IFN-α/ribavirin (PEG-IFN/RBV) combination therapy in different populations with HCV infections. Here, we test the hypothesis that diversity in the p7, NS2 and NS3 genes influences the probability of obtaining either a sustained (SVR) or non-sustained (non-SVR) viral response in Chinese patients with genotype 1b chronic hepatitis C. There were significantly more unique variations in the p7, NS2 and NS3 genes in the sequences from SVR than non-SVR patients. Inter-patient variations related to treatment outcome in NS3 were concentrated in the protease domain. There were no significant differences in the frequency of variations in the core, E1 and E2 proteins between the groups. In conclusion, increased amino acid sequence diversity in the p7, NS2 and NS3 genes is associated with an SVR to PEG-IFN/RBV therapy in Chinese patients with genotype 1b chronic hepatitis C.
Journal
Archives of Virology – Springer Journals
Published: Jun 1, 2012